(The scientific sessions were held Nov. 12-16 in Orlando.) | ||||
Company (Location) |
Product |
Description |
Indication |
Status (Date)# |
Amarin Corp. plc (Dublin, Ireland) |
AMR101 |
A prescription-grade omega-3 fatty acid |
High triglycerides |
Phase III data showed patients who were on statin therapy experienced a significant reduction in triglyceride levels and other lipid parameters, as well as inflammatory biomarkers, when treated with AMR101 (11/17) |
Genzyme Corp. (Cambridge, Mass.) |
MIPO |
Mipomersen |
Low-density lipoprotein cholesterol |
Positive results from a randomized, double-blind, placebo-controlled Phase II trial showed that weekly treatment reduced LDL-C by 47% compared to 2% with placebo (11/17) |
Regado Biosciences Inc. (Basking Ridge, N.J.) |
REG1 |
Anticoagulant system; reversible antithrombotic agent |
Cardiovascular disease |
Phase IIb data suggested it provided nearly complete Factor IXa inhibition with a dose of 1 mg/kg of pegnivacogin and, when followed by 75% and 100% reversal doses of anivamersen, resulted in numerically lower rates of ischemic events compared with heparin (11/16) |
Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue. # The date indicated refers to the BioWorld Today issue in which the news item can be found. |